Replimune Group, Inc.: stock overview

REPLNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$19.07

November 20, 2026Market cap $1.8B

What Ploutos Investor adds for Replimune

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from FY2017
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

It holds more cash than debt, by $184M. It pays no dividend.

From its SEC filings (latest fiscal year to March 31, 2026) and the price of November 20, 2026.

Its SEC filings
Market cap
$1.8B
94.80M shares
P/E
–
Revenue, 12 months
–
Net margin
–

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2024–FY2026 fiscal years
  • FY2026Mar 31, 202610-K
    Revenue–
  • FY2025Mar 31, 202510-K
    Revenue–
  • FY2024Mar 31, 202410-K
    Revenue–

Fiscal years in figures

REPL's revenue, profit, cash flow and dividend with each year-end price, from FY2017 to FY2023, 7 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $642M
$1.8B
Enterprise value 
$1.6B
P/E 
–
EV / EBIT 
–
EV / Revenue 
–
P/B 3-year median: 1.8
8.8
FCF yield 3-year median: -38.1%
–
Earnings yield 3-year median: -39.7%
–

Profitability

Net margin 
–
ROIC 
-101.3%
ROIC, 5-year average 
-47.4%
ROE 
-142.6%

Growth

Sorry, we do not have enough data

for the “Growth” group

Balance sheet

Cash 
$308M
Total debt 
$127M
Of which operating leases 
$3.1M
Net cash 
$184M
Net debt / EBITDA 
–
Interest cover 
-35.8x
Current ratio 
7.11

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+8.9%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Replimune Group, Inc.
Exchange
NASDAQ
Industry (SIC)
2836 · Biological Products, (No Diagnostic Substances)
Fiscal year ends
March 31
Latest annual report
March 31, 2026
Reporting currency
USD
Shares
94.80M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Replimune's filings show?

These are Replimune's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about REPL

Didn't find what you were looking for?

Ask us
What is REPL's market cap?

Replimune Group, Inc.'s market cap is $1.8B, at a price of $19.07 on November 20, 2026 and 94.80M shares.

Does REPL pay a dividend?

No. Replimune paid no regular dividend over the last 12 months.

Where do the figures come from?

From Replimune Group, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.